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Background: Newcastle disease virus (NDV), a single-stranded RNA virus of the family Paramyxoviridae, is a
candidate virotherapy agent in cancer treatment. Promising responses were observed in clinical studies. Despite its
high potential, the possibility of the virus to develop a persistent form of infection in cancer cells has not been
investigated. Occurrence of persistent infection by NDV in cancer cells may cause the cells to be less susceptible to
the virus killing. This would give rise to a population of cancer cells that remains viable and resistant to treatment.
Results: During infection experiment in a series of colorectal cancer cell lines, we adventitiously observed a
development of persistent infection by NDV in SW480 cells, but not in other cell lines tested. This cell population,
designated as SW480P, showed resistancy towards NDV killing in a re-infection experiment. The SW480P cells
retained NDV genome and produced virus progeny with reduced plaque forming ability.
Conclusion: These observations showed that NDV could develop persistent infection in cancer cells and this factor
needs to be taken into consideration when using NDV in clinical settings.
Keywords: Newcastle disease virus, Persistent infection, Colorectal cancer cell lineIntroduction
Newcastle disease virus is a negative-stranded RNA virus
belonging to the family of Paramyxoviridae of the genus
Avulavirus. Its high preference to infect cancer cells [1]
have made it as one of the widely studied candidate
agent for oncolytic virotherapies. Due to its promising
potential, NDV strains NDV-HUJ, PV701, MTH-68/H
and NV1020 are now being tested as cancer therapeutics
in clinical trials [2-4]. Despite their promising preclinical
findings [4], further advancement in the clinical use of
NDV is still debatable even though their mechanistic in-
sights are well studied [reviewed in 4]. The risks in-
volved in using viruses as therapeutic agents include
problems with mutant viruses having increased patho-
genic properties [5] and potential development of per-
sistent infections [6].
Viruses have the ability to establish a persistent infec-
tion in host cells. This type of infection may exist in the
forms of silent or productive infections [6]. Cells, which* Correspondence: nshafee@upm.edu.my
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unless otherwise stated.have been persistently infected by viruses, remained vi-
able in the forms of latent, chronic or slow infections
[6]. The ability of enveloped negative strand RNA viruses
such as arboviruses, paramyxoviruses, vesicular stoma-
titis virus (VSV) and rabies virus to develop persistent
infections in host cells has been well documented [7-10].
The forms of ‘incomplete’ viruses [10-12] involved in
these persistent infections were referred to as defective
interfering particles (DIPs). For oncolytic viruses, devel-
opment of persistent infections can lead to reduced
virus-induced cytotoxicity [13]. It can also create popula-
tions of cells that have reduced permissiveness to wild-
type viruses [10-13]. This phenomenon was previously
reported for the oncolytic reovirus, where wild type reo-
virus cause reduced infection in persistently infected
cells [14].
Development of persistent infections by NDV was first
reported in the late 60s and early 70s [7-13]. These stud-
ies, however, only reported the occurrence of persistent
infections in normal cells. Since NDV has shown great
potential as an anticancer agent in clinical studiesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment in persistent infection in cancer cells is imperative.
Thus far, occurrence of persistent infection in cancer
cells by a velogenic strain of NDV has not been described,
even though its establishment in normal cells had been re-
ported [8-12]. Therefore, in the present study, we reported
the development of persistent infection by NDV in a sub-
population of SW480 colon cancer cells. These findings
contribute additional data needed in the tailoring of NDV,
particularly of a velogenic strain, as oncolytic virotherapy
agent in clinical settings.
Results
Detection of a subpopulation of cancer cells that are
resistant to NDV cytolysis
During the course of our investigation into the oncolytic
activities of NDV strain AF2240 in human colorectal cancer
(CRC) cell lines, we inadvertently observed the existence of
a subpopulation of SW480 cell line that was resistant to
NDV killing. To characterize these resistant cancer cells,
we attempted further culturing and propagation of theFigure 1 Viability and morphology of CRC cancer cell lines following
times intervals post-infection with NDV strain AF2240. At 96 hours post-infe
(B) The remaining cells in the infected SW480 continued to proliferate follo
morphological features to the parental SW480 population.cells based on their continued proliferation and mor-
phological observation. This population of cells origi-
nated from the remaining viable SW480 cells after 96
hpi (Figure 1A). Even though SW620, DLD-1, Dks8,
HCT116p53+/+, HCT116p53-/-, and HT29 CRC cell lines
also contained approximately 10-30% viable cells at this
time post-infection, they died within 7 days following
media replacement. The remaining cells in the infected
SW480, on the other hand remained viable and they con-
tinued to proliferate following media replacement. The
resulting population of cells was designated as SW480P.
These cells retained similar morphological features to the
parental SW480 population (Figure 1B). A complete con-
fluency of the SW480P on flask surfaces was achieved
within approximately 10 days after the media replacement.
SW480P cells are less susceptible to NDV-induced cytolysis
The existence of a subpopulation of cancer cells that were
resistant to NDV killing was suggestive of a persistent type
of viral infection [6]. For oncolytic viruses, these persistently
infected cells tend to be less susceptible to virus-inducedNDV infection. (A) Viability of CRC cancer cell lines following selected
ction, only less than 40% cells remained viable across all the cell lines.
wing media replacement. These cells (SW480P) retained similar
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whether this phenomenon occur in the SW480P, a re-
infection studies were performed. Re-infection of the
SW480P cells with the same multiplicity of infection (MOI)
as the initial SW480 infection, did not result in cell death
even after 96 hpi (Figure 2A). The cells instead continued to
divide at almost the same multiplication rate as the mock-
infected SW480 population. Even though a slightly slower
replication rate was noted in the infected SW480P during
the first 24 hours of infection, it stabilized to the level of
SW480 afterwards. Infected SW480, on the other hand
displayed the expected pattern of reduced cell viability as
the infection period progressed. In addition to the absence
of susceptibility to NDV killing, infected SW480P cells also
failed to show any obvious cytopathic effects (CPE) after
72 hpi (Figure 2B, left panel). A parallel infection in the
parental SW480, on the other hand, showed the typical pat-
tern of CPE due to NDV infection (Figure 2B, right panel).Figure 2 Susceptibility of SW480P cells to NDV-induced cytolysis. (A)
The cells were re-infected with the similar MOI as the initial SW480 infectio
effects (CPE) after 72 hpi while the parental SW480 displayed the typical paNDV genes and proteins were detectable in the SW480P
cells
Resistance of the SW480P towards NDV-induced killing
during the re-infection experiment was suggestive of a
persistent NDV infection in the cells. Characteristics of
persistently infected cells include reduced virus-induced
cytotoxicity and a deregulation of antiviral response [17].
This was perhaps coincided with the presence of viral
RNA and protein synthesis [11] within the hosts’ tran-
scriptional and translational machineries. To investigate
whether the SW480P cells retained NDV genes and pro-
teins, we performed RT-PCR and immunofluorescent
analyses as described in the Materials and methods. RT-
PCR amplification showed a DNA band with a size of
1.7 kb, which was the expected size of an amplified nu-
cleocapsid protein (NP) gene of NDV. This DNA band
was seen in the positive control (Figure 3A, lane C2)
and the SW480P samples (Figure 3A), regardless whetherViability of re-infected SW480P cells compared to the parental SW480.
n. (B) The infected SW480P cells did not show any obvious cytopathic
ttern of CPE due to NDV infection.
Figure 3 Detection of NDV genes and proteins in the SW480P cells. (A) RT-PCR analysis on DNA samples of SW480 and SW480P cells
infected and mock infected with NDV. A DNA band with a size of 1.7 kb appeared in selected samples. (B) Immunofluorescent analyses of the
infected and control cells using a monoclonal antibody against the NP protein of NDV. A speckled pattern of green antigen staining was visible
in the cytoplasm of cells.
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hand, no such band was seen in the negative control
(Figure 3A, lane C1) and the mock-infected SW480
samples (Figure 3A).
Since DNA band of a similar size to the amplified NP
gene was detected in the mock-infected SW480P cells, we
were interested to see whether NDV proteins were also
present in the samples. Immunofluorescent staining using
a monoclonal antibody against the NP protein of NDV
gave a positive detection in the mock-infected SW480P
cells (Figure 3B, left panel). A speckled pattern of antigen
staining (green) in the cytoplasm of cells, particularly in
the perinuclear regions, was noted. Almost all the cells
had this staining pattern. A positive staining for the NP
protein was also seen in the infected SW480P as well as in
the infected SW480 cells. No such staining was present in
the mock-infected SW480 suggesting that the staining was
specific for the NP protein of NDV.SW480P cells maintained a productive NDV infection,
secreting virus progeny with reduced plaque-forming
ability
Detection of NDV genome as well as proteins in the
mock-infected SW480P suggested that the cells had
been persistently infected with the virus, and were ac-
tively producing viral proteins. To further characterize
the type of persistent infection [6] that occured in the
cells, we determined whether any infectious viral pro-
genies or just DIPs were being secreted by the cells. To
achieve this, we performed a plaque assay [18] using
spent culture media of the mock-infected SW480P cells.
Results showed that plaques were formed (Figure 4A,
top panel). However, their sizes were smaller than the
plaques formed from the media of infected parental
SW480 (Figure 4A, middle panel). These smaller plaque-
forming virus progenies were designated as ‘mutant’
NDV (mNDV) particles. The majority of plaques from
Figure 4 Detection of infectious viral progenies secreted into cell culture media. (A) A plaque assay was performed using spent culture
media of the mock-infected SW480P and control cells. Different plaque morphologies were visible in the different samples. (B) A graphical
representation of the number of plaques of less than 1 mm or in the range of 1-4 mm is shown.
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than 1 (±0.05) mm while those from the infected SW480
media had a range of 1-4 mm. Media from the re-
infected SW480P cells (after 96 hpi; Figure 4A, bottom
panel), gave rise to a mixed morphology of plaques with
diameters ranging from 0.5-4 mm. Upon closer examin-
ation, the number of small plaques (less than 1 mm) was
lesser than the number of the bigger ones (1-4 mm) by a
ratio of approximately 1:10.
Counting of the plaques showed that the undiluted
spent media of the mock-infected SW480P had 66 pfu/
ml of infectious virus progenies (Figure 4B), almost all ofwhich were less than 1 mm in size. This was in contrast
to the media from the infected parental SW480 and re-
infected SW480P, where higher numbers of bigger pla-
ques (1-4 mm) were seen. The number of total secreted
infectious virus progeny was significantly higher in the
infected parental SW480 cells compared to the SW480P
cells. This was true even when the SW480P cells were
re-infected with NDV.
mNDV were infectious towards HT29 cells
Development of persistent infections was commonly
associated with the production of ‘incomplete’ viruses
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tion without the presence of suitable helper viruses.
Plaque assay results in the present study showed that
mNDV particles from the mock-infected SW480P cul-
ture media were able to infect and gave rise to plaques
despite at smaller sizes. To investigate whether their in-
fectivity on another colorectal cancer cell line was also
retained, we performed infections in HT29 cells. HT29
cells were previously shown to be susceptible to NDV
oncolytic activities [19]. Spent culture media collected
from the mock-infected SW480P cells were used to in-
fect HT29 as described in the Materials and methods
section. After 24 hpi, viability of the infected HT29 cells
remained around 90% (Figure 5). This value was differ-
ent from the value of cells infected with the wild-type
NDV, where only around 10% of cells were still viable.
Higher percentage of viable HT29 cells was seen in the
mNDV-infected culture compared to the wild type
NDV-infected cells throughout the infection period.
Even after 96 hpi, more than 70% of the mNDV-infected
HT29 cells continued to be viable. This finding con-
firmed that mNDV remained infectious albeit at lower
infectivity in HT29 CRC cells.
Discussion
Development of persistent infection by oncolytic viruses
may interfere with their efficacy as anticancer agents. This
form of infection in target cells can affect wild type virus
tropism as well as the cells permissiveness to reinfection
[1]. It also caused a decrease in virus-induced cytotoxicity
[13,20]. Data on the occurrence of persistent infections by
a number of oncolytic viruses, such as Reovirus, Vesicular
stomatis virus (VSV), measles, adenovirus and herpes sim-
plex virus (HSV) were previously reported [20-24]. Up to
now, there has been no report on the relationship of velo-
genic strain of NDV and persistent infection in cancer
cells, despite the fact that the lentogenic strain of the virusFigure 5 Infectivity of mNDV on HT29 cells. mNDV was infectious
towards HT29 cells, however it resulted in less killing effect. The cells
were infected using spent culture media from the mock-infected
SW480P cells as described in the Materials and methods section.is now in phases 1 and 2 clinical trials [4]. Development of
persistent infection by NDV in normal cells, on the other
hand, had also been well studied in normal cells [8-12],
but not in cancer cells.
In the present study, we observed that a viscerotropic-
velogenic strain of NDV [25] was able to develop persist-
ent infection in a type of CRC cells, specifically the
SW480 cell line. No such infection was observed in the
other CRC cell lines tested. Further investigation into
the contribution of genotypic differences among the cell
lines towards NDV susceptibility and infection outcome
are currently being investigated in our laboratory. The
persistently-infected cells designated as SW480P, arose
from a small subpopulation of cells which survived the
primary round of NDV infection. SW480 cell line was
also shown to be susceptible to cytolysis by other onco-
lytic viruses such as echoviruses [26]. This observation
supports our data of the existence of persistently in-
fected SW480 cells by NDV.
Persistent infection can be divided into latent, chronic,
and slow infections [6]; each with its own unique char-
acteristics that influence cellular changes. The lack of
morphological changes in the SW480P versus SW480
cells, as well as the presence of viral NP proteins in al-
most all of the SW480P cells, were strongly suggestive of
a slow type of persistent infection [6]. The absence of cell
death, the occurrence of infectious virus secretion and the
high fraction of antigen-positive cells in SW480P nar-
rowed down the infection to a chronic diffuse type of per-
sistent infection.
Previously, a plaque assay using media from persist-
ently infected normal mouse cells on chicken embryonic
fibroblasts also showed the formation of smaller plaques
[10]. Even though the host cells were different in the as-
says, their data supported our observation that NDV can
cause persistent infection. In the current study, we ob-
served the occurence of a persistent infection in cancer
cells. Such observation has not been previously reported
in NDV infections.
These findings suggest that even though SW480P
maintains a low level of productive NDV infection, they
themselves are still susceptible to infection by the wild
type NDV. On another note, the progeny virus, the
mNDV, secreted by the SW480P cells retained their in-
fectivity, hence they were unlikely to be in the form of
DIPs per se. The DIPs are characterized by their inability
to infect cells on their own due to large genetic muta-
tions [27]. This mNDV virus was also able to infect
another colorectal cancer cell line, HT29 [19] albeit at
lower cytotoxicity. This suggested that the mNDV
maintained its infectivity in other cancer cells besides
the parental cells.
The fact that NDV was able to establish persistent in-
fection in SW480 cells, but not in other cell lines tested,
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NDV infection in SW480 cells or the cells’ responses to
the infection. To the best of our knowledge, until now
only the lentogenic strains of NDV were evaluated in clin-
ical studies [18]. This might be due to the specific regula-
tions by the World Organization for Animal Health on
the use of notifiable diseases and viruses with velogenic
properties. Further investigation into the pathogenesis and
oncolytic properties of the viscerotropic-velogenic strain
of NDV, such as the one used in the study, would add to
the understanding of their detail mechanistic actions.
These data would contribute towards tailoring of velo-
genic NDV specificity in the clinical settings.
Materials and methods
NDV propagation
A viscerotropic-velogenic NDV strain AF2240 [25] was
propagated in 9-day-old embryonated chicken eggs as pre-
viously described [28]. After 48 h of incubation, the in-
fected allantoic fluid was harvested and clarified by
centrifugation at 5000 × g. Virus was purified using a su-
crose gradient centrifugation at concentrations of 20 to
60% at 200,000 × g for 4 h. A band observed around the
middle of the gradient, which represented the concen-
trated virus, was pipetted and diluted with 1 × PBS (Sigma)
followed by another centrifugation at 200,000 × g for 4 h.
The resulting pure virus pellet was resuspended with 1 ×
PBS, aliquoted and kept in -80°C until used. NDV is en-
demic in Malaysia and categorized as a BSL2 pathogen
based on NIH, US and Japan guidelines [29,30].
All experiments were performed in BSL2 biosafety cabi-
net. Extra precautions were taken to ensure there was not
leakage of the virus to the environment. Waste and all in-
struments were sterilized and decontaminated after use.
Cell lines and infection by NDV
CRC cell lines; SW620, SW480, DLD-1, Dks8, HCT1
16p53+/+, HCT116p53-/-, and HT29, were generous gifts
from Prof. Eric J. Stanbridge, University of California, Ir-
vine, USA. Cells were maintained in RPMI1640 media
(PAA, Austria) supplemented with 10% (v/v) fetal bovine
serum (FBS; PAA, Austria). For infection, cells were
seeded for overnight followed by infection with NDV
[18] at a 2.0 MOI. Cell viability was determined using the
trypan blue exclusion assay. Experiments were repeated
at least twice and a representative of the replicates was
presented.
Rescue of viable cells following NDV infection
After 96 h of infection, media containing floating cells
were removed. Fresh growth media was added to the
remaining attached cells. Cells were incubated for ap-
proximately two weeks with an addition of 4 ml of fresh
growth media every 3 days. The surviving cells werethen trypsinized and sub-cultured into new tissue cul-
ture flasks. For a re-infection experiment, the recovered
cells were seeded and infected as described in the infec-
tion procedure above. Confirmation of NDV infection
was performed using RT-PCR and immunofluorescent
staining. Virus infectivity was quantitated using the
plaque assay method [18].RT-PCR
Total RNA samples were harvested using the TriReagent
(Invitrogen, USA) following the manufacturer’s proto-
cols. First strand cDNA was then synthesized using the
Reverse Transcription System (Promega) in a thermal
cycler (MJ Research Inc. USA). Forward (5′- AAT GAA
TTC TG ATG TCT TCC GTA TTC GAT G -3′) and re-
verse (5′-AAT CTC GAG C TCA ATA CCC CCA GTC
GGT GT -3′) primers were used to amplify the NDV
NP gene using 30 PCR cycles. The conditions were 94°C
for 30 s, 55°C for 1 min, and 72°C for 1.5 min, followed
by a final extension step of 72°C for 7 min. The resulting
PCR product was electrophoresed, stained with ethidium
bromide and viewed with a Gel Documentation Imaging
System (BioRad, USA).Immunofluorescent detection of NDV NP protein
Infected cells on cover slips were washed with 1 × PBS
and fixed with 4% paraformaldehyde, followed by
permeabilization with 0.1% Triton-X 100 for 10 min. All
dilutions of reagents were performed in PBS. After
blocking with 1% BSA, cells were probed with a primary
monoclonal antibody against the NP protein of NDV
[31] for overnight. The bound antibody was then de-
tected with an FITC-conjugated secondary antibody
(Santa Cruz Biotechnology, sc-2010) and counterstained
with propidium iodide. Samples were then visualized
using a fluorescent microscope (DFC420C, Leica) and
images were captured using a DM2500 (Leica) camera.Statistical analysis
Student’s t-test was used to analyze the experimental
data throughout the study. Results were expressed as
mean ± standard error of the mean of at least two inde-
pendent experiments. Statistical significance was defined
as p-value < 0.05. All the tests were performed using
Windows Microsoft Excel 2010 (Microsoft Corporation,
Seattle, WA).
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